Ahmed Hamimes, Hani Amir Aouissi, Feriel Kheira Kebaili, Zeinab A Kasemy
{"title":"使用泊松自回归(PAR)模型研究阿尔及利亚COVID-19传染动力学的贝叶斯方法","authors":"Ahmed Hamimes, Hani Amir Aouissi, Feriel Kheira Kebaili, Zeinab A Kasemy","doi":"10.1080/10543406.2025.2489361","DOIUrl":null,"url":null,"abstract":"<p><p>Global emphasis has been focused on tracking the trends of the COVID-19 pandemic. Numerous techniques have been developed or utilized for this purpose. In this study, we seek to present and evaluate a model that, in our opinion, has not received adequate attention, using Algeria as a case study. We developed two distinct Poisson autoregressive (PAR) models using the Monte Carlo Markov Chain (MCMC) simulation method and the Bayesian method: one based solely on short-term dependence and the other incorporating both short- and long-term dependence. The study aimed to apply these models to enhance the prediction of new infections and determine whether the disease is spreading or declining. This information can guide decisions on implementing or relaxing containment measures. Our findings suggest that Algeria's epidemiological state was relatively stable at the end of the study period, with the combined long-term and short-term dependence factors being less than 1 (<math><mi>α</mi><mo>+</mo><mi>β</mi><mo>=</mo><mn>0.994</mn><mo>)</mo></math>. This indicates that while the epidemic is in decline, the infection rates are not expected to drop significantly in the near future. Furthermore, the short-term dependence parameter <math><mi>α</mi><mo>=</mo><mn>0.987</mn></math>constitutes a significant portion (99%) of the total dependence. This high value of <math><mi>α</mi></math> suggest that the COVID-19 epidemic in Algeria is experiencing a strong decline, though the rate of new infections is expected to persist at a lower level for the foreseeable future. Given these findings, it is recommended that authorities remain vigilant and continue public health measures, including educational campaigns and awareness efforts, to promote COVID-19 vaccination and adherence to health guidelines.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-17"},"PeriodicalIF":1.2000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Bayesian approach for studying COVID-19 contagion dynamics in Algeria using a Poisson autoregressive (PAR) model.\",\"authors\":\"Ahmed Hamimes, Hani Amir Aouissi, Feriel Kheira Kebaili, Zeinab A Kasemy\",\"doi\":\"10.1080/10543406.2025.2489361\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Global emphasis has been focused on tracking the trends of the COVID-19 pandemic. Numerous techniques have been developed or utilized for this purpose. In this study, we seek to present and evaluate a model that, in our opinion, has not received adequate attention, using Algeria as a case study. We developed two distinct Poisson autoregressive (PAR) models using the Monte Carlo Markov Chain (MCMC) simulation method and the Bayesian method: one based solely on short-term dependence and the other incorporating both short- and long-term dependence. The study aimed to apply these models to enhance the prediction of new infections and determine whether the disease is spreading or declining. This information can guide decisions on implementing or relaxing containment measures. Our findings suggest that Algeria's epidemiological state was relatively stable at the end of the study period, with the combined long-term and short-term dependence factors being less than 1 (<math><mi>α</mi><mo>+</mo><mi>β</mi><mo>=</mo><mn>0.994</mn><mo>)</mo></math>. This indicates that while the epidemic is in decline, the infection rates are not expected to drop significantly in the near future. Furthermore, the short-term dependence parameter <math><mi>α</mi><mo>=</mo><mn>0.987</mn></math>constitutes a significant portion (99%) of the total dependence. This high value of <math><mi>α</mi></math> suggest that the COVID-19 epidemic in Algeria is experiencing a strong decline, though the rate of new infections is expected to persist at a lower level for the foreseeable future. Given these findings, it is recommended that authorities remain vigilant and continue public health measures, including educational campaigns and awareness efforts, to promote COVID-19 vaccination and adherence to health guidelines.</p>\",\"PeriodicalId\":54870,\"journal\":{\"name\":\"Journal of Biopharmaceutical Statistics\",\"volume\":\" \",\"pages\":\"1-17\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-04-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biopharmaceutical Statistics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10543406.2025.2489361\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2489361","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
A Bayesian approach for studying COVID-19 contagion dynamics in Algeria using a Poisson autoregressive (PAR) model.
Global emphasis has been focused on tracking the trends of the COVID-19 pandemic. Numerous techniques have been developed or utilized for this purpose. In this study, we seek to present and evaluate a model that, in our opinion, has not received adequate attention, using Algeria as a case study. We developed two distinct Poisson autoregressive (PAR) models using the Monte Carlo Markov Chain (MCMC) simulation method and the Bayesian method: one based solely on short-term dependence and the other incorporating both short- and long-term dependence. The study aimed to apply these models to enhance the prediction of new infections and determine whether the disease is spreading or declining. This information can guide decisions on implementing or relaxing containment measures. Our findings suggest that Algeria's epidemiological state was relatively stable at the end of the study period, with the combined long-term and short-term dependence factors being less than 1 (. This indicates that while the epidemic is in decline, the infection rates are not expected to drop significantly in the near future. Furthermore, the short-term dependence parameter constitutes a significant portion (99%) of the total dependence. This high value of suggest that the COVID-19 epidemic in Algeria is experiencing a strong decline, though the rate of new infections is expected to persist at a lower level for the foreseeable future. Given these findings, it is recommended that authorities remain vigilant and continue public health measures, including educational campaigns and awareness efforts, to promote COVID-19 vaccination and adherence to health guidelines.
期刊介绍:
The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:
Drug, device, and biological research and development;
Drug screening and drug design;
Assessment of pharmacological activity;
Pharmaceutical formulation and scale-up;
Preclinical safety assessment;
Bioavailability, bioequivalence, and pharmacokinetics;
Phase, I, II, and III clinical development including complex innovative designs;
Premarket approval assessment of clinical safety;
Postmarketing surveillance;
Big data and artificial intelligence and applications.